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Background: Coronary artery disease (CAD) is associated with an increased risk for sudden cardiac death.
Randomized controlled trials have shown that implantable cardioverter defibrillators (ICD) improve life expectancy
unless they are implanted within the first days after an acute myocardial infarction and guidelines recommend their
use. We aimed to validate that these results also apply to patients of a typical community hospital in Germany.
Methods: This was a retrospective analysis of patients undergoing coronary angiography in the Lippe-Detmold
Hospital between 2003 and 2006. They had to have significant CAD and an ejection fraction (EF)≤ 35% and no
acute myocardial infarction within 28 days of implantation and no history of ventricular fibrillation.
Results: 213 patients were included; 70 of which received an ICD. Patients with an ICD implantation were younger
(64.8 ± 9.9 vs. 67.9 ± 9.8 years; p = 0.034), had single vessel CAD more frequently (22.9 vs. 11.2%; p = 0.025) and a
lower EF (26.7 ± 6.3 vs. 29.1 ± 4.6%; p = 0.006). Hospital readmissions were comparable between the ICD and the
control group (68.6 vs. 72.0%; p = 0.602). ICD therapy was associated with a considerable survival benefit compared
to conventional therapy (HR 0.52; 95%CI 0.29-0.93; p = 0.027) in a Cox-Proportional Hazards Regression analysis.
Conclusions: Appreciating the potential limitations of retrospective studies, we found that ICD use was associated
with improved survival in patients with significant CAD and an EF <= 35% typical for a large tertiary hospital.
Keywords: Implantable cardioverter defibrillator, Cohort study, Myocardial infarctionBackground
Coronary artery disease (CAD) is associated with an
increased risk for angina, acute myocardial infarction
(MI), reduced left ventricular ejection fraction (LVEF),
congestive heart failure, and sudden cardiac death [1].
Although considerable progress has been made with re-
spect to improving prognosis [2] approaches utilizing
antiarrhythmic pharmacotherapy have been misleading
[3-6], and sudden cardiac death remains a major threat
to patients wellbeing. MADIT II documented that ICD
use was associated with improved survival in CAD* Correspondence: peter.bramlage@ippmed.de
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distribution, and reproduction in any mediumpatients with prior MI and reduced LV function (EF ≤
30%) [7] while DINAMIT reported no benefit with re-
spect to overall mortality in patients with ICD implant-
ation within days after an acute myocardial infarction [8].
ICD therapy is recommended by the recent guidelines
for the primary prevention of ventricular arrhythmias
and sudden cardiac death in patients with LV dysfunc-
tion due to prior MI who are at least 40d post-MI and
have an LVEF ≤ 30-40%, NYHA II and a good reasonable
expectation of survival with a good functional status for
more than 1 year (Level of Evidence A) [9]. In clinical
practice, ICDs appear to reduce all cause and
arrhythmic death to a similar degree as in primary pre-
vention trials [10]. We aimed to validate the results of
the aforementioned trial in clinical practice by aCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Patients characteristics
Control ICD p
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plantation between 2003 and 2006.(n = 143) (n = 70)
Age in years, mean (±SD) 67.9 ± 9.8 64.8 ± 9.9 0.034
Gender, women, n (%) 26 (18.2 %) 6 (8.6 %) 0.065
Coronary artery disease (CAD)
1-vessel CAD, n (%) 16 (11.2 %) 16 (22.9 %) 0.025
2-vessel CAD, n (%) 41 (28.7) 23 (32.9) 0.531
3-vessel CAD, n (%) 86 (60.1) 31 (44.3) 0.029
Left ventricular ejection 29.1 ± 4.6 26.7 ± 6.3 0.006Methods
This was a retrospective analysis of patients undergoing
coronary angiography in the cardiology unit of the
Lippe-Detmold Hospital, a tertiary care hospital, be-
tween January 8th 2003 and December 18th 2006. Ethic
committee approval as well as patient informed consent
was not obtained due to the retrospective design of the
study.fraction (LVEF), %
LVEF, women, % 29.4 ± 4.5 28.7 ± 7.7
LVEF, men, % 29.0 ± 4.7 26.5 ± 6.1
LVEF, 1-vessel CAD, % 29.4 ± 4.2 26.3 ± 7.0
LVEF, 2-vessel CAD, % 28.7 ± 4.7 25.2 ± 7.1
LVEF, 3-vessel CAD, % 29.3 ± 4.7 28.1 ± 5.0
Diabetes, n (%) 56 (39.2) 24 (34.3) 0.490
Pharmacotherapy, n (%)
Betablockers 132 (93.0) 68 (97.1) 0.215Patients
Patients included had undergone coronary angiography
because of significant CAD and an EF ≤ 35% on mono-
plane evaluation and had an indication for the primary
prevention of ventricular arrhythmias and sudden car-
diac death [9]. Exclusion criteria were acute myocardial
infarction less than 28 days ago, known cancer (because
of the limited life expectancy), and cardio-pulmonary re-
suscitation due to ventricular fibrillation.ACE inhibitors 110 (77.5) 59 (84.3) 0.245
ARBs 19 (13.4) 6 (8.6) 0.307
Statins 93 (65.5) 57 (81.4) 0.017
Diuretics 125 (88.0) 58 (82.9) 0.303
Antiarrhythmics (Amiodarone) 6 (4.2) 3 (4.3) 0.984
Anticoagulation 51 (35.9) 27 (38.6) 0.706
Legend: ARB, Angiotensin II Receptor Blockers; CAD, coronary artery disease;
ICD, implantable cardioverter defibrillator, LVEF, left ventricular ejection
fraction; SD, standard deviation.Documentation
Follow-up data for a duration of at least 30 months were
collected from hospital charts when patients were re-
admitted or via contact by telephone. The following
variables were obtained: date of birth, gender, the pres-
ence of CAD and the number of vessels diseased, LVEF,
the presence of diabetes and concomitant medication.
During follow-up data on readmissions to the hospital
and the reasons for referral, the adequacy of shocks and
overall duration of survival were gathered.Statistics
This data were analyzed with Aabel 20/20 data vision 3W
from Gigawiz Ltd Co. Descriptive statistics were applied,
based on available data and significance calculated using
the two-tailed unpaired t-Test. Kaplan-Meier estimates
used to compare survival and the p-value calculated by
the log-rank test. Further a proportional hazards model
was built considering variables displaying significant dif-
ferences at baseline (p< 0.05).Results
Patient characteristics
A total of 213 patients (70 receiving an ICD, 143 receiv-
ing none, 15.0% female) were included into this analysis
(Table 1). Patients in the ICD group were significantly
younger, had single vessel CAD more frequently and a
lower ejection fraction. Except for the use of statins,
which was more frequent in patients receiving an ICD,
pharmacotherapy was not different between groups.Therapy
On follow-up hospital readmissions in the ICD group
were comparable to the CT group (Table 2). Reasons
were rhythm disorders, ICD related reasons and a de-
compensation of heart failure, which was more frequent
in the ICD group. In the control group there were seven
late ICD implants and two patients received a cardiac
resynchronization device (CRT-D). In the ICD group
one device was upgraded to a CRT-D.Survival
ICD therapy was associated with a significant survival
benefit compared to conventional therapy (HR 0.52; 95%
CI 0.29-0.93; p = 0.027) in a Cox-Proportional Hazards
Regression analysis. Curves began to diverge at 24 months
of follow-up (Figure 1, Table 3). This benefit was pre-
served in patients with the longest follow-up of 78 months.
There were a nominally larger proportion of patients with
inappropriate (those not due to ventricular fibrillation)
ICD shocks within the group of patients dying (21.4 vs.
5.4%; p = 0.0896, exact fisher test).
Table 2 Complications after inclusion and ICD therapy
Complications after inclusion Control ICD p
(n = 143) (n = 70)
Hospital Admissions, n (%) 103 (72.0) 48 (68.6) 0.602
Rhythm disorders, n (%) 18 (12.6) 12 (17.1) 0.369
Heart failure, n (%) 13 (5.1) 18 (37.1) <0.001
Late implants
Time from EF to ICD / CRT (months) 33.1 ± 20.7 2.3 ± 4.4
Late ICD implantation, n (%) 7 (4.9) -
CRT-D implantation, n (%) 2 (1.4) -
CRT-D upgrade, n (%) - 1 (1.4)
ICD therapy (n = 70) Survivor Death p
(n= 56) (n = 14)
ICD shock, n (%) 15 (26.8) 4 (28.6) 1.000
Inappropriate* shocks, n (%) 3 (5.4) 3 (21.4) 0.090
No ICD shocks, n (%) 38 (67.9) 9 (64.3) 1.000
Legend: ICD, implantable cardioverter defibrillator; Time from EF to ICD, time
between determination of EF (Ejection Fraction) and ICD implantation; CRT-D,
cardiac resynchronization device; *as inappropiate those shocks were classified
that were not due to ventricular fibrillation.
Table 3 Outcomes of patients in our registry
Detmold ICD + Detmold ICD –
(n = 70) (n = 143)
Coronary artery disease with an EF≤ 35 %,
no MI within the last 28 days, without known
cancer or history of ventricular fibrillation
Mean follow-up 44 months
Total mortality 20.0 37.8




Legend: HR, hazard ratio; CI, confidence interval, EF, ejection fraction; LV, left
ventricular.
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Guideline recommendations for the primary prevention
of ventricular arrhythmias and sudden cardiac death
such as that of the ACC/AHA/ESC [9] rely on informa-
tion derived from randomized, controlled trials. These
trials have a high internal validity for the patient group


















Figure 1 Probability of survival: 0.0; 0.2; 0.4; 0.6; 0.8; 1.0 - Kaplan-M
therapy. Legend: ICD, implantable cardioverter defirbillator.substantial proportion of patients in clinical practice.
Therefore we aimed to validate these trials in the patient
population of our community hospital in Detmold.
Overall 213 patients were retrospectively documented
and prospectively evaluated for survival and appropriate-
ness of shocks. We found that ICD use was associated
with a considerable improvement of survival which was
statistically significant.Study population
Patients in the present registry were included if they
had CAD with an EF ≤ 35% and no MI within the last
28 days. This patient population is only partially present
in most of the ICD trials [8,11-15], but has a substantial
overlap with those of MADIT-II [7], which includeds of follow-up
ayer overall survival in patients receiving ICD vs. conventional
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EF ≤ 30%. Therefore Table 4 displays clinical characteris-
tics of patients in both MADIT-II and our observation
and illustrates that while age, gender and diabetes
prevalence was roughly comparable, LVEF was less
reduced in our observation (because of the inclusion of
patients with an EF ≤ 35 vs. ≤ 30%). Diuretic use was
nominally less in MADIT-II (76%) than in our observa-
tion (86%). More patients received betablockers, ACE-
inhibitors and (at least for ICD patients) statins; antiar-
rhythmic use was substantially lower (4 vs. 15%). This
might be attributable to the fact that our patients were
included between 2003 and 2006 after the publication of
MADIT-II, for which patients were included between
1997 and 2001. These data illustrate that patients from
recent registries such as our observation might have a
differential profile to randomized, controlled trials con-
ducted previously. With the more frequent use of opti-
mal medical therapy patient prognosis has been so
much improved that absolute risks for cardiovascular
events and total mortality might differ substantially be-
tween respective patients [2].Survival benefit in perspective
Both MADIT-II and our observation document improve-
ments in overall survival which may reach about 31%
such as in MADIT-II [7]. This is also compatible with
SCD-HeFT, which reported a risk reduction of 23% (HRTable 4 Clinical characteristics of patients in the MADIT II
trial
MADIT II ICD + MADIT II ICD –
(n = 742) (n = 490)
Prior myocardial infarction more than
28 days ago and an EF≤ 30%
Age (years) 64 ± 10 65 ± 10
Female Gender (%) 16 15
LVEF (%± SD) 23 ± 5 23± 6
Pharmacotherapy
Betablockers (%) 70 70




Mean follow-up 20 months
Total mortality 14.2 19.8




Legend: HR, hazard ratio; CI, confidence interval, EF, ejection fraction; LV, left
ventricular.0.77; p = 0.007) and an absolute decrease in mortality of
7.2% after five years in the overall population. Patients in
SCD-HeFT were included based on NYHA class II or III
heart failure and a LVEF ≤ 35% and followed for a median
of 45.5 months. In comparison MADIT reported a risk
reduction of 54% for patients with prior MI, and LVEF ≤
35% (absolute risk 38.6 vs. 15.8%) and a documented
episode of asymptomatic unsustained ventricular tachy-
cardia; and inducible, non suppressible ventricular
tachyarrhythmia on electrophysiologic study [11].
Against this background the risk reduction of 48% in our
cohort appears high. This might have been due to con-
founders that we were not able to fully account for. For
example there were more patients with triple vessel dis-
ease in the control compared to the ICD group (60.1 vs.
44.3%; p = 0.006).
The difference to our data on those of MADIT II is
reasonable given that patients with previous proof of
arrhythmia were specifically included. None of the
patients in the ICD group and 9.8% of the control
group died of primary arrhythmia which illustrates a
stronger risk reduction for arrhythmic death. Data are
however hard to compare due to substantial differences
in antiarrhythmic drug use. For example MUST
reported a reduced 5 year rate of cardiac arrest or
arrhythmic death by 27% (HR 0.73) among patients
with CAD, a LVEF ≤ 40% and asymptomatic, not sus-
tained ventricular tachycardia [16].
Heart failure and inappropriate shocks
An increased risk for heart failure was documented in
our observation and also in the MADIT-II trial (Tables 1
and 4). Recently an analysis of risk factors for recurrent
heart failure in the MADIT-II trial was published [17]:
Risk factors for a first HF hospitalization included treat-
ment with an ICD (HR 1.31; p = 0.05), NYHA class> II
(HR 1.95; p< 0.001), female gender (HR 1.38; p = 0.05),
atrial fibrillation (HR 1.90; p = 0.001), QRS >120 ms (HR
1.41; p = 0.01), diabetes mellitus (HR 1.51; p = 0.003),
heart rate ≥80 (HR 1.35; p = 0.04), diuretic therapy (HR
1.82; p< 0.001), and the presence of prerenal azotemia
(blood urea nitrogen:creatinine >20; HR 1.45; p = 0.01).
The occurrence of one HF event after enrolment was
associated with a 2.8-fold (p< 0.001) increase in the risk
of death, whereas after the occurrence of a second event
there was a 6.7-fold (p< 0.001) increase in the risk of
subsequent mortality.
Inappropriate shocks (those not due to ventricular fib-
rillation) were also more frequent in patients dying
within the observational period (although not signifi-
cant). This has been associated to the presence of atrial
fibrillation (odds ratio 6.2) in a recent analysis of 549
patients with heart failure and ICDs [18]. In a Chinese
single center study documenting 34 patients between
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were documented [19]. They found these to be again
related mainly to supraventricular tachyarrhythmias, es-
pecially atrial fibrillation. We were however not able to
verify this association because of the low number of
cases in our observation.
Limitations
These data reproduce those found in prior randomized
controlled trials. Although this is encouraging a number
of limitations have to be acknowledged in addition to
the ones mentioned before: 1) This was a retrospective
study with all limitations inherent in such designs such
as: significant bias that may affect the assignment to the
treated group or the control group, incompleteness of
data which were not fully captured to answer the ques-
tion under investigation, difficulty in assessing a tem-
poral or even causal relationship, reliance on the quality
of data available with no possibility of verification. 2)
The set of data obtained for the patients under investiga-
tion was limited so that data interfering with the out-
come such those on renal function, biomarkers or the
presence of atrial fibrillation were not considered in the
analysis. 3) We were not able to report on different
causes of death (such as arrhythmic) and only report
overall survival. 4) Third the study is small allowing no
detailed analyses and multiple adjustments due to lim-
ited power. 5) There is a slight imbalance in the degree
of heart failure, age and the number of vessels diseased
which may not have been adequately accounted for. 6)
We obtained no reasons why one group was offered an
ICD and the other group not thought both had an indi-
cation for ICD use.
Conclusions
Appreciating the potential limitations of retrospective
studies we found that, in patients with ischemic heart
disease and left ventricular dysfunction, typical for those
in the community setting, ICD use was associated with
an improved survival. The benefits were however offset
by heart failure and inappropriate shocks which may jus-
tify the further research into more advanced devices
such as biventricular pacemakers.
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